22 / 27
K
EY
P
OINTS
In patients treated with lenvatinib, the occurrence of hypertension, diarrhoea, proteinuria, or hypothyroidism
was generally associated with longer OS in patients with uHCC in this posthoc exploratory analysis.
Association between overall survival (OS) and adverse events with
lenvatinib treatment in patients with hepatocellular carcinoma
(REFLECT)
•
In REFLECT, lenvatinib showed a different AE profile from that of sorafenib
•
Patients who received lenvatinib experienced more instances of
hypertension, proteinuria, dysphonia, and hypothyroidism than patients
who received SOR.
•
Recently, hypertension in lenvatinib treated patients with differentiated thyroid
cancer was shown to be correlated with improved efficacy
•
This analysis showed that OS was longer in patients who had several AE’s of
interest than those who did not (table 1)
AE
AEI
n(%)
No AEI
n(%)
Hazard Ratio for
OS
95% CI
P-value
Hypertension
201 (42%)
277 (58%)
0.64
0.52-0.80
0.00005
Diarrhoea
184 (38%)
294 (62%)
0.72
0.58-0.90
0.00314
Proteinuria
117 (24%)
361 (76%)
0.76
0.60-0.98
0.03042
Dysphonia
113 (24%)
365 (76%)
0.86
0.68-1.11
0.24708
Hypothyroidism 78 (16%)
400 (84%)
0.72
0.54-0.96
0.02377
1. Sung M et al. Presented at ASCO GI 2019